Cargando…

Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure

BACKGROUND: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear examination for acid fast bacilli without performing culture. This may lead to erroneous...

Descripción completa

Detalles Bibliográficos
Autores principales: Ambreen, Atiqa, Jamil, Muhammad, Rahman, Mohammad Aqeel ur, Mustafa, Tehmina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822412/
https://www.ncbi.nlm.nih.gov/pubmed/31666021
http://dx.doi.org/10.1186/s12879-019-4561-7
_version_ 1783464329589293056
author Ambreen, Atiqa
Jamil, Muhammad
Rahman, Mohammad Aqeel ur
Mustafa, Tehmina
author_facet Ambreen, Atiqa
Jamil, Muhammad
Rahman, Mohammad Aqeel ur
Mustafa, Tehmina
author_sort Ambreen, Atiqa
collection PubMed
description BACKGROUND: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear examination for acid fast bacilli without performing culture. This may lead to erroneous treatment outcomes as viable bacteria may be missed due to the low sensitivity of direct smear method. The aim of this study was to investigate if sterilizing cure is achieved among the new pulmonary TB cases declared cured by sputum smear conversion and to evaluate the impact of addition of ethambutol in the continuation phase in achieving it. METHODS: New sputum smear-positive pulmonary TB patients registered at a tertiary care hospital in Pakistan from November 2013 to March 2014 were followed under standard Directly Observed Treatment Short Course strategy for 6 months. Half of these patients received ethambutol in addition to isoniazid and rifampicin in the continuation phase. Sputum specimens were examined on microscopy at 2 months and at the end of treatment. Sputa of patients with negative direct smear examination at the end of treatment were cultured. RESULTS: Among 5746 TB suspects, 1595 were new sputum smear positive pulmonary TB cases, and 533 were registered at our hospital. Among these, 504 converted sputum negative at 2 months and 348 converted at the end of 6 months of treatment and were declared cured. Sputa of 204/348 patients were cultured, and 12/204 (6%) were culture-positive. Culture positivity at 6 months was not associated with bacterial load, smoking, diabetes, presence of cavities, history of contact with TB patients, age, sex, socioeconomic status, or addition of ethambutol in the continuation phase. CONCLUSION: Viable cultivable bacilli were detected in 6% of cured patients, which would have significant impact on the control of TB. This highlights the need for an inexpensive and accurate surrogate marker for culture as it is not feasible to perform culture in routine for monitoring treatment response in the low-resource settings. The treatment outcome did not improve by addition of ethambutol emphasizing the need to find the optimal duration of treatment for individual or carefully selected groups of patients.
format Online
Article
Text
id pubmed-6822412
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68224122019-11-06 Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure Ambreen, Atiqa Jamil, Muhammad Rahman, Mohammad Aqeel ur Mustafa, Tehmina BMC Infect Dis Research Article BACKGROUND: Pulmonary tuberculosis (TB) with detectable Mycobacterium tuberculosis in the sputum is a major source of transmission. In resource limited TB endemic settings, cure is declared through sputum smear examination for acid fast bacilli without performing culture. This may lead to erroneous treatment outcomes as viable bacteria may be missed due to the low sensitivity of direct smear method. The aim of this study was to investigate if sterilizing cure is achieved among the new pulmonary TB cases declared cured by sputum smear conversion and to evaluate the impact of addition of ethambutol in the continuation phase in achieving it. METHODS: New sputum smear-positive pulmonary TB patients registered at a tertiary care hospital in Pakistan from November 2013 to March 2014 were followed under standard Directly Observed Treatment Short Course strategy for 6 months. Half of these patients received ethambutol in addition to isoniazid and rifampicin in the continuation phase. Sputum specimens were examined on microscopy at 2 months and at the end of treatment. Sputa of patients with negative direct smear examination at the end of treatment were cultured. RESULTS: Among 5746 TB suspects, 1595 were new sputum smear positive pulmonary TB cases, and 533 were registered at our hospital. Among these, 504 converted sputum negative at 2 months and 348 converted at the end of 6 months of treatment and were declared cured. Sputa of 204/348 patients were cultured, and 12/204 (6%) were culture-positive. Culture positivity at 6 months was not associated with bacterial load, smoking, diabetes, presence of cavities, history of contact with TB patients, age, sex, socioeconomic status, or addition of ethambutol in the continuation phase. CONCLUSION: Viable cultivable bacilli were detected in 6% of cured patients, which would have significant impact on the control of TB. This highlights the need for an inexpensive and accurate surrogate marker for culture as it is not feasible to perform culture in routine for monitoring treatment response in the low-resource settings. The treatment outcome did not improve by addition of ethambutol emphasizing the need to find the optimal duration of treatment for individual or carefully selected groups of patients. BioMed Central 2019-10-30 /pmc/articles/PMC6822412/ /pubmed/31666021 http://dx.doi.org/10.1186/s12879-019-4561-7 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Ambreen, Atiqa
Jamil, Muhammad
Rahman, Mohammad Aqeel ur
Mustafa, Tehmina
Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
title Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
title_full Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
title_fullStr Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
title_full_unstemmed Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
title_short Viable Mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
title_sort viable mycobacterium tuberculosis in sputum after pulmonary tuberculosis cure
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822412/
https://www.ncbi.nlm.nih.gov/pubmed/31666021
http://dx.doi.org/10.1186/s12879-019-4561-7
work_keys_str_mv AT ambreenatiqa viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure
AT jamilmuhammad viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure
AT rahmanmohammadaqeelur viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure
AT mustafatehmina viablemycobacteriumtuberculosisinsputumafterpulmonarytuberculosiscure